# An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

> **NCT02932891** · PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** DSXS topical

## Key facts

- **NCT ID:** NCT02932891
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-04-14
- **Final completion:** 2017-12-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02932891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02932891, "An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02932891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*